Acute In-Patient Unit, Dr. R. Lafora Psychiatric Hospital, Madrid, Spain.
Pharmacopsychiatry. 2011 Jun;44(4):142-7. doi: 10.1055/s-0031-1279728. Epub 2011 Jun 27.
The association of antipsychotics is a widespread therapeutic resource in clinical practice. The purpose of the present work was to evaluate the efficacy and safety of amisulpride augmentation in patients responding at least partially to olanzapine.
In this observational 3-months open-label investigation, we evaluated the effectiveness of the addition of amisulpride to 49 subjects, after having scored at least 25 on the brief psychiatric rating scale (BPRS) following olanzapine monotherapy for 6 weeks. Patients were assessed at baseline, 1 and 3 months using the BPRS, the clinical global impression severity of illness (CGI-S) scale and the Udvalg for Kliniske Undersogelser side effect rating scale (UKU).
In subjects who were at least partially responsive to monotherapy with olanzapine, coadjuvant treatment with amisulpride achieved a statistically significant improvement in mental status over a 3 month period as measured by the BPRS, CGI and UKU scales. The response rate (>20% reduction in BPRS score) was 75.51%.
Amisulpride augmentation, in a group of patients partially or non-responsive to olanzapine, may lead to an improvement in schizophrenic symptoms. However, these results are subject to several limitations making it difficult to derive firm clinical recommendations, and underscoring the need for future research into the value of these therapeutic alternatives in poor responders.
抗精神病药的联合应用是临床实践中广泛应用的治疗资源。本研究的目的是评估在至少对奥氮平部分反应的患者中，联用氨磺必利的疗效和安全性。
在这项为期 3 个月的开放性标签观察研究中，我们评估了在奥氮平单药治疗 6 周后，BPRS 评分至少增加 25 分的 49 例患者中，联用氨磺必利的效果。患者在基线、1 个月和 3 个月时使用 BPRS、临床总体印象严重程度量表（CGI-S）和 Udvalg for Kliniske Undersogelser 副作用评定量表（UKU）进行评估。
在至少对奥氮平单药治疗部分或无反应的患者中，与奥氮平合用氨磺必利在 3 个月的时间内，在精神状态方面取得了显著改善，BPRS、CGI 和 UKU 量表均有统计学意义。应答率（BPRS 评分降低>20%）为 75.51%。
在对奥氮平部分或无反应的患者中，联用氨磺必利可能会改善精神分裂症症状。然而，这些结果受到多种限制，难以得出明确的临床建议，并强调需要进一步研究这些治疗选择在反应不佳者中的价值。
